Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALXN1830 in Warm Autoimmune Hemolytic Anemia (WAIHA)
NCT04956276Phase 2Withdrawn
- Sponsor
- Alexion Pharmaceuticals
- Start
- Jan 2022
- Primary completion
- Jul 2022
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of orilanolimab in warm autoimmune hemolytic anemia (wAIHA) (5 cohorts), sponsored by Alexion Pharmaceuticals. Primary endpoint: Proportion Of Participants Achieving A >= 2 g/dL Increase In Hemoglobin From Baseline To The End Of Primary Treatment at Week 12. Planned start Jan 2022; status: withdrawn.
02
Drugs
orilanolimab
03
Conditions
warm autoimmune hemolytic anemia (wAIHA)
Beyond the preview
Go deeper on NCT04956276.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04956276.